# NIPT Explained: What Non-Invasive Prenatal Testing Screens For

> A clear, OB-reviewed guide to how cell-free DNA screening works, which chromosomal conditions it covers, when to do it, how accurate it is, and what a result—positive or not—actually means for your pregnancy.

*Published 2026-06-25 · By Priya Nair, MD*

The short answer
NIPT is a blood test performed as early as 9 weeks that analyzes placental DNA circulating in the mother's bloodstream to screen for Down syndrome and other chromosomal differences. It is highly sensitive but is a screening tool, not a diagnosis — a positive result always requires confirmatory testing before any clinical decision is made.

When your provider mentions "cell-free DNA screening" or "NIPT" at your first prenatal visit, it can feel like a lot of unfamiliar language arriving at once. The test itself is simple — just a blood draw — but what it measures, what it can and cannot tell you, and how to interpret results deserve a clear, unhurried explanation. As an OB-GYN who discusses prenatal genetic testing with patients every day, I want to walk you through the science, the numbers, and the decisions in plain language.

*This article is general educational information. It is not a substitute for a conversation with your own obstetrician, midwife, or genetic counselor, who can apply this information to your specific pregnancy.*

## How Does NIPT Work — What Is Cell-Free DNA?

During pregnancy, the placenta sheds small fragments of DNA into the mother's bloodstream. These fragments, called **cell-free DNA (cfDNA)**, contain genetic material that reflects the chromosomal makeup of the pregnancy. NIPT works by drawing a small sample of maternal blood, isolating and sequencing all the cfDNA fragments present — both the mother's own DNA and the placental DNA — and then using computational analysis to detect whether any chromosomes appear in abnormal quantities.

The proportion of total cfDNA that comes from the placenta is called the *fetal fraction*. A fetal fraction of at least 4% is generally required for a reliable result; below that threshold, most labs report an inconclusive or "no-call" result and recommend redrawing at a later gestational age. By 9 to 10 weeks of gestation, fetal fraction is typically sufficient for testing in most pregnancies.

The three leading commercial NIPT laboratories use different technologies to analyze cfDNA. **Natera Panorama** uses a single-nucleotide polymorphism (SNP)-based approach that reads thousands of specific genetic positions simultaneously, allowing it to distinguish maternal from fetal DNA with particular precision — making it the only NIPT that can screen for triploidy and determine twin zygosity. **Myriad Prequel** uses a proprietary amplification method called Amplify that boosts the measurable fetal fraction, achieving the lowest published no-call rate (below 0.1%) of the three — an important advantage for individuals with elevated BMI, in whom low fetal fraction is more common. **Labcorp MaterniT21 PLUS** employs genome-wide counting across all 23 chromosome pairs and is the only test clinically validated for triplet or higher-order multiple pregnancies.

All three tests can be performed from a blood draw at 9 to 10 weeks, with results typically available within 7 to 14 calendar days.

## What Conditions Does NIPT Screen For?

Every major NIPT covers the same core set of conditions. Understanding what each one means helps you read your report with clarity.

**The three common trisomies** — in which a fetus has three copies of a chromosome instead of the usual two — account for the majority of chromosomal conditions detected by NIPT:

  - **Trisomy 21 (Down syndrome)** — the most common chromosomal condition in live births; associated with intellectual disability and a range of physical differences. NIPT detects it with approximately 99% sensitivity.

  - **Trisomy 18 (Edwards syndrome)** — a severe chromosomal condition associated with complex organ differences; most affected pregnancies do not survive to term. NIPT detects it with 97–98% sensitivity.

  - **Trisomy 13 (Patau syndrome)** — another severe condition associated with brain, heart, and kidney differences. NIPT sensitivity ranges from 91 to 100% in published studies, with [false-positive rates below 0.2% for all three common trisomies](https://pmc.ncbi.nlm.nih.gov/articles/PMC9522523/).

**Sex chromosome aneuploidies (SCAs)** involve an abnormal number of X or Y chromosomes. All major NIPTs screen for monosomy X (Turner syndrome, 45,X), Klinefelter syndrome (47,XXY), 47,XYY, and 47,XXX. Importantly, the *positive predictive value (PPV)* for SCAs is considerably more variable than for common trisomies — monosomy X PPV in unselected populations ranges from only 20 to 29%, meaning most positive monosomy X results are false positives. This is one reason why confirmatory testing is always recommended.

**Microdeletions** are small missing segments of chromosomal material. The most clinically significant is 22q11.2 deletion syndrome (DiGeorge syndrome), associated with heart defects and immune differences, which all major panels include. ACOG has specifically noted that cfDNA screening for microdeletions has not been validated to the same standard as common trisomies, and that PPVs for rare microdeletions are considerably lower — making confirmatory testing even more important when a microdeletion is flagged.

Most panels also offer optional reporting of **fetal sex**, which is distinct from the chromosomal findings. You can request this information be withheld if you prefer to find out another way.

A note on what NIPT does not screen for
NIPT does not assess fetal anatomy, detect open neural tube defects, screen for single-gene disorders (such as cystic fibrosis or sickle cell disease — that is the role of carrier screening), or provide any information about the placenta or amniotic fluid. It is one piece of the prenatal information picture, not a comprehensive fetal assessment.

## How Accurate Is NIPT — and What Does a Positive Result Actually Mean?

This is where the nuance matters most, and where patients are most often left confused by results letters that feel less clear than they should be.

NIPT is highly accurate in the sense of *sensitivity*: it catches the vast majority of affected pregnancies. A meta-analysis of more than 200,000 pregnancies found that NIPT detects over 99% of trisomy 21 pregnancies. That is substantially better than first-trimester combined screening (nuchal translucency plus bloodwork), which detects approximately 79–96% of Down syndrome pregnancies at a 3–5% false-positive rate.

However, the number that determines how worried you should be about a *positive* result is not sensitivity — it is **positive predictive value (PPV)**: the probability that a positive test corresponds to a real chromosomal condition. PPV is governed by how common the condition is in the population being tested.

Because trisomy 21 is more common in live births than trisomy 13, and because maternal age raises baseline risk, PPV varies significantly:

  Approximate NIPT Positive Predictive Value by Condition (General Obstetric Population)

      Condition
      Approximate PPV Range
      Clinical Implication

      Trisomy 21 (Down syndrome)
      65–86%
      Majority of positives are true; confirmatory testing recommended

      Trisomy 18
      35–58%
      Meaningful false-positive rate; always confirm

      Trisomy 13
      18–25%
      Majority of positives are false positives; confirmation essential

      Monosomy X (Turner syndrome)
      20–29%
      Most positives are false positives; CPM is common driver

      Klinefelter syndrome (47,XXY)
      68–70%
      Higher PPV among SCAs; confirmation still required

Data from: [PMC9261060](https://pmc.ncbi.nlm.nih.gov/articles/PMC9261060/), Positive predictive value estimates for noninvasive prenatal testing, PubMed Central.

Maternal age modifies PPV substantially. Women 35 and older have higher baseline chromosomal risk, so a positive NIPT carries more weight: in one large study, PPV for the combined common trisomies was 64.9% in women 35-plus versus 45.8% in younger women. In pregnancies with multiple compounding risk factors, combined T21/T18/T13 PPVs approached 97%.

**The practical bottom line:** a positive NIPT result is a signal that warrants follow-up, not a diagnosis. [ACOG's 2026 Practice Advisory](https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2026/01/screening-for-fetal-chromosomal-abnormalities) and the November 2025 SMFM Consult Series No. 74 both reinforce that patients should not make irreversible decisions based on a positive NIPT alone, without confirmatory diagnostic testing. CVS or amniocentesis — analyzed by chromosomal microarray — is the only path to a definitive answer.

## When to Do NIPT, and What Happens After Results

NIPT is typically ordered at the first prenatal appointment, between 9 and 13 weeks. It requires only a standard blood draw — no needles near the uterus, no procedure-related miscarriage risk. Results arrive within one to two weeks and are reviewed by your provider, who can explain whether the result is low-risk (the most common outcome), high-risk (indicating possible chromosomal difference), or inconclusive (requiring a redraw).

**If your result is low-risk,** no further chromosomal workup is typically needed unless there are other clinical concerns such as an abnormal anatomy scan or elevated nuchal translucency measurement. A low-risk NIPT does not guarantee a chromosomally typical pregnancy — NIPT is a screening tool with sensitivity, not 100% certainty — but it substantially lowers probability of the conditions screened.

**If your result is high-risk,** your provider will discuss confirmatory diagnostic options. CVS can be performed from 10 to 13 weeks; amniocentesis from 15 weeks onward. Both retrieve fetal genetic material for chromosomal microarray analysis, which is now ACOG's recommended analytic method because it detects submicroscopic copy-number variants that a standard karyotype misses. Both carry a small but real procedure-related miscarriage risk (approximately 1 in 769 for amniocentesis and 1 in 455 for CVS in experienced hands, per ACOG Practice Bulletin No. 162). Your genetic counselor will help you weigh this against the probability that the NIPT finding is real.

**On cost and insurance:** self-pay costs with manufacturer assistance programs typically fall under $300, but without coverage, bills can exceed $1,000 or more. Coverage has improved: Cigna and Aetna now cover NIPT for all pregnant individuals regardless of age. Other insurers may still require a documented indication. Call your insurer before the blood draw, and ask your provider's office which laboratory is in-network.

All three major laboratories — Natera, Myriad Genetics, and Labcorp — provide free access to board-certified genetic counselors, which is worth using regardless of your result. Genetic counselors are trained to translate screening statistics into the context of your specific pregnancy, age, and history in a way that a brief provider appointment often cannot fully cover.

## Sources

1. [Non-invasive prenatal testing for the detection of trisomy 13, 18, and 21 and sex chromosome aneuploidies in 68,763 cases](https://pmc.ncbi.nlm.nih.gov/articles/PMC9522523/)
2. [Screening for Fetal Chromosomal Abnormalities — Practice Advisory](https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2026/01/screening-for-fetal-chromosomal-abnormalities)
3. [The implementation and impact of non-invasive prenatal testing (NIPT) for Down's syndrome into antenatal screening programmes: A systematic review and meta-analysis](https://pmc.ncbi.nlm.nih.gov/articles/PMC11098470/)
4. [Positive predictive value estimates for noninvasive prenatal testing from data of a prenatal diagnosis laboratory and literature review](https://pmc.ncbi.nlm.nih.gov/articles/PMC9261060/)
5. [Understanding Noninvasive Prenatal Testing (NIPT) — Panorama](https://www.natera.com/resource-library/panorama/understanding-noninvasive-prenatal-testing-nipt/)
6. [First Trimester Screening, Nuchal Translucency and NIPT](https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/first-trimester-screening-nuchal-translucency-and-nipt)
7. [Comparing Prenatal Genetic Tests (NIPT): BilliontoOne Unity, LabCorp MaterniT21, Myriad Prequel, and Natera Panorama](https://allay-life.com/comparing-prenatal-genetic-tests-nipt-billiontoone-unity-test-labcorp-maternit21-test-myriad-prequel-test-and-natera-panorama-test/)
8. [NIPT Information for Obstetric Care Providers](https://dph.illinois.gov/topics-services/life-stages-populations/genomics/fact-sheets/nipt-providers.html)

---
Source: https://natalnew.com/prenatal-care/nipt-explained
Index: https://natalnew.com/llms.txt · Full text: https://natalnew.com/llms-full.txt